Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
· finance.yahoo.com
The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.
Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Du...